ACTRN12617001330336
Completed
Phase 1
A Phase 1, Single-Center, Randomized, Placebo-Controlled, Ascending Single-Dose Study of the Pharmacokinetics, Safety, and Tolerability of Oral XG005 in Healthy Volunteers
Xgene Pharmaceutical Inc.0 sites50 target enrollmentSeptember 18, 2017
ConditionsChronic Pain
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Chronic Pain
- Sponsor
- Xgene Pharmaceutical Inc.
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A Phase 1 Single-Center, Randomized, Placebo-Controlled, Double-Blind Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Candidate Topical Antimicrobial (NEO101) in the Reduction of Propionibacterium acnes among Healthy Young Adult MePropionibacterium acnes amongst healthy volunteersSkin - Dermatological conditionsACTRN12606000424505eosil, Inc.30
Completed
Phase 1
A phase 1, randomized, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic profiles of OLX10010 in healthy subjects compared to placeboISRCTN64317949OliX Pharmaceuticals, Inc.48
Completed
Not Applicable
A Phase 1, Single-Center, Single-Blind, Placebo and Propofol Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous (IV) Infusion Doses of ABP-700anesthesiaNot applicableNL-OMON41980Annovation Biopharma, Inc. (a wholly owned subsidiary of The Medicines Company, Inc.)72
Completed
Phase 1
A Phase 1 Randomized, Placebo-Controlled, Single & Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of GLY-200 in Healthy Adult SubjectsType 2 DiabetesMetabolic and Endocrine - DiabetesACTRN12621000800820Glyscend Pty Ltd64
Completed
Not Applicable
Phase I, Single-Center, Randomized, Placebo-Controlled, Double-Blinded Study with Single Ascending Doses, Evaluating the Safety and Tolerability of T20K, Administered by a 1-hr IV Infusion in Healthy Male VolunteersNL-OMON48273Cyxone AB40